This article only represents the author's own views.
China’s BeiGene Ltd. (6160.HK; 688235.SH; BGNE.US) has underlined its status as a rising star of the global drugs industry, posting a big jump in quarterly sales of its trademark cancer medicines.
But the upstart drug developer is facing resistance from other top brands in the field of cancer therapy, and has yet to find a path into profit.
您已閱讀6%（393字），剩餘94%（6359字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。